Evidence map›Paper›PMID 41907624›Full record

SynthesisFrontiers in oncology2026

The value of artificial intelligence in ultrasound imaging for predicting molecular subtypes of breast cancer: a meta-analysis.

Yu-Hang Cheng, Jian Dong, Zhen Wang, Huan Zhao, Ming Chen, Ting Ma

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu-Hang Cheng *Department of Ultrasound Medicine, the First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.
Jian Dong *Department of Ultrasound Medicine, the First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.
Zhen WangDepartment of Ultrasound Medicine, the First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.
Huan ZhaoDepartment of Ultrasound Medicine, the First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.
Ming ChenDepartment of Ultrasound Medicine, the First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.
Ting MaDepartment of Ultrasound Medicine, the First Affiliated Hospital of Shihezi University, Shihezi, Xinjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The study aims to integrate an evaluation of the accuracy and validity of ultrasonography based artificial intelligence (AI) algorithms for predicting the molecular subtypes of breast cancer patients through a meta-analysis. Methods: A search of the PubMed, Embase, Web of Science, and Cochrane Library databases was performed to locate relevant literature, and the reported studies before February 2026 were included. We evaluated the quality of the studies included by utilizing the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) questionnaire. Two evaluators independently searched for literature and assessed the quality of literature included in the study. Results: A total of thirteen studies assessing a number of 13615 patients of breast cancer were included. The results demonstrated that ultrasonic imaging combined with artificial intelligence algorithm has promising accuracy and effectiveness to predict molecular subtypes of breast cancer. The pooled sensitivity and specificity were 0.89 (95%CI: 0.82-0.93) and 0.82 (95%CI: 0.77-0.86), respectively. Additionally, the diagnostic odds ratios (DOR), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) were 32.10 (95%CI: 18.60-55.38), 4.84 (95%CI:3.80-6.17), and 0.14 (95%CI: 0.09-0.22). The area under the curve (AUC) was 0.91 (95%CI: 0.88-0.93). Publication bias was not significantly observed. Conclusions: Ultrasonic imaging based on artificial intelligence algorithm has good performance and application prospects for forecasting breast cancer molecular subtypes. This technique can help establish the molecular subtype of breast cancer before operation, offering effective help for the treatment plan. It may reduce unnecessary biopsy, which is anticipated to become a meaningful implement in clinical application. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024599983, identifier CRD42024599983.

Indexed as

artificial intelligencebreast cancerconvolutional neural networkdeep learningmolecular subtypes

Identifiers

PMID41907624
PMCPMC13017395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.